/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

T

Toyoaki Hida

Sapporo Medical University(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

445

Papers

28.7K

Citations

75

h-index

210

i10-index

Toyoaki Hida is an academic researcher from Sapporo Medical University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 75, co-authored 379 publications.

ORCID: 0000-0003-3537-0020

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

Papers by this author

works

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · The Lancet · 2,108 citations

https://doi.org/10.1016/s0140-6736(19)32222-6

Luis Paz‐Ares Mikhail Dvorkin Yuanbin Chen Niels Reinmuth

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 · The Lancet Oncology · 747 citations

https://doi.org/10.1016/s1470-2045(14)70381-x

Takashi Seto Terufumi Kato Makoto Nishio Kōichi Goto

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

2015 · Annals of Oncology · 327 citations

https://doi.org/10.1093/annonc/mdv186

Mark G. Kris D. Ross Camidge Giuseppe Giaccone Toyoaki Hida

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

2020 · Journal of Thoracic Oncology · 192 citations

https://doi.org/10.1016/j.jtho.2020.09.022

Julien Mazières Achim Rittmeyer Shirish M. Gadgeel Toyoaki Hida

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

2017 · ESMO Open · 106 citations

https://doi.org/10.1136/esmoopen-2017-000219

Fiona Blackhall D. Ross Camidge Alice T. Shaw Jean‐Charles Soria

Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells

2009 · Carcinogenesis · 79 citations

https://doi.org/10.1093/carcin/bgp097

Koji Kawaguchi Hideki Murakami Tetsuo Taniguchi Makiko Fujii

Research topics

topics

Lung Cancer Treatments and Mutations

Lung Cancer Research Studies

Lung Cancer Diagnosis and Treatment

Colorectal Cancer Treatments and Studies

Cancer Immunotherapy and Biomarkers

Chat about Author

Papers

Chat

Click to start Chat